Benkinson CR 125 Capsule

Brand Name: Benkinson CR

• Manufacturer: Incepta Pharmaceuticals Ltd.

• Generic Name: Levodopa + Benserazide

• Strength: 100mg + 25mg

• Presentation: Capsule

• Category: Anti-Parkinson's Agent

Indication:

• Parkinson's syndrome with motor fluctuations.

Dosage & Administration:

• Patients not presently receiving levodopa: 1 capsule of Benkinson CR 125, 3 times/day.

• Patients previously on levodopa-benserazide immediate release preparation: Initially dose should substitute every 100 mg of Levodopa with 1 controlled-release capsule, given at the same dosage frequency as before. Increase every 2-3 days according to response.

Side Effects:

• Anxiety

• Appetite decreased

• Arrhythmia

• Depression

• Diarrhea

• Hallucination

• Movement disorders

• Nausea

• Postural hypotension

• Sleep disorders

• Altered taste

• Vomiting

• Leucopenia

Precautions:

• Cushing's syndrome

• Diabetes mellitus

• Endocrine disorders

• History of convulsions

• History of myocardial infarction with residual arrhythmia

• History of peptic ulcer

• Hyperthyroidism

• Osteomalacia

• Pheochromocytoma

• Psychiatric illness

• Severe cardiovascular disease

• Severe pulmonary disease

• Susceptibility to angle-closure glaucoma

Contraindications:

• Hypersensitivity to levodopa-benserazide or any of the excipients

• Patients receiving non-selective monoamine oxidase (MAO) Inhibitors

• Decompensated endocrine, renal or hepatic function

• Cardiac disorders

• Psychiatric diseases with a psychotic component

• Closed angle glaucoma

• Suspicious, undiagnosed lesions or a history of melanoma

• Patients less than 30 years old